OKYO Pharma's CEO will present on urcosimod's development for neuropathic corneal pain at a Boston summit on May 22, 2025.
Quiver AI Summary
OKYO Pharma Limited, a clinical-stage biopharmaceutical company focused on therapies for neuropathic corneal pain and inflammatory eye diseases, announced that CEO Dr. Gary S. Jacob will present at the 4th Annual GPCRs-Targeted Drug Discovery Summit in Boston on May 22, 2025. The presentation will detail the development of OKYO’s lead drug candidate, urcosimod, aimed at treating neuropathic corneal pain (NCP), a debilitating condition causing severe eye discomfort. Urcosimod, a chemerin peptide agonist, has shown promise in treating NCP and dry eye disease, demonstrating significant results in a recent Phase 2 trial for dry eye patients and currently being evaluated for NCP. OKYO Pharma is committed to advancing innovative treatments for these conditions and is publicly traded on NASDAQ.
Potential Positives
- Dr. Gary S. Jacob, CEO of OKYO Pharma, will present at the 4th Annual GPCRs-Targeted Drug Discovery Summit, which enhances the company's visibility and credibility within the biopharmaceutical industry.
- The presentation focuses on urcosimod, the company's lead clinical drug candidate, which addresses a significant unmet medical need for neuropathic corneal pain, highlighting OKYO's potential impact on patient care.
- Urcosimod has demonstrated statistical significance in a Phase 2 trial for dry eye disease, indicating its therapeutic potential and enhancing investor confidence in the company’s pipeline.
Potential Negatives
- The limited patient population (17 patients) in the recently completed Phase 2 trial for neuropathic corneal pain may raise concerns about the robustness and generalizability of the trial results.
- Despite initial positive results, the lack of FDA approved treatments for neuropathic corneal pain indicates a high unmet medical need and potential market challenges for Urcosimod.
- Urcosimod's development has not yet progressed beyond Phase 2 trials, which may suggest a slower timeline for potential market entry compared to competitors.
FAQ
What is neuropathic corneal pain (NCP)?
NCP is a debilitating condition causing severe eye discomfort due to nerve damage and inflammation in the cornea.
Who will present at the GPCRs-Targeted Drug Discovery Summit?
Dr. Gary S. Jacob, CEO of OKYO Pharma, will present at the summit on May 22, 2025.
What is urcosimod?
Urcosimod is OKYO's lead drug candidate designed to treat neuropathic corneal pain and dry eye disease.
When is Dr. Jacob's presentation scheduled?
Dr. Jacob's presentation is scheduled for Thursday, May 22, 2025, at the Revere Hotel in Boston, MA.
What stage is OKYO Pharma in its drug development?
OKYO Pharma is a clinical-stage company developing therapies for neuropathic corneal pain and dry eye disease.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$OKYO Hedge Fund Activity
We have seen 3 institutional investors add shares of $OKYO stock to their portfolio, and 3 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- DAUNTLESS INVESTMENT GROUP, LLC added 1,988,780 shares (+inf%) to their portfolio in Q1 2025, for an estimated $2,525,750
- BARCLAYS PLC removed 961,000 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $1,220,470
- FNY INVESTMENT ADVISERS, LLC added 20,000 shares (+inf%) to their portfolio in Q1 2025, for an estimated $25,400
- CITADEL ADVISORS LLC added 6,675 shares (+32.2%) to their portfolio in Q1 2025, for an estimated $8,477
- UBS GROUP AG removed 2,998 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $3,807
- RENAISSANCE TECHNOLOGIES LLC removed 2,554 shares (-15.5%) from their portfolio in Q1 2025, for an estimated $3,243
- GEODE CAPITAL MANAGEMENT, LLC added 0 shares (+0.0%) to their portfolio in Q1 2025, for an estimated $0
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
LONDON and NEW YORK, May 19, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic corneal pain, a severe ocular condition without an FDA approved therapy, and for inflammatory eye diseases, announced that its CEO, Gary S. Jacob, Ph.D., will be giving an oral presentation at the 4 th Annual GPCRs-Targeted Drug Discovery Summit in Boston, MA on May 22, 2025. Dr. Jacob’s presentation will cover the development of urcosimod, OKYO’s lead clinical drug candidate, to treat neuropathic corneal pain (NCP) which is a debilitating condition affecting many tens of thousands worldwide, and is characterized by chronic, severe eye discomfort.
Presentation Information:
Event: 4th Annual GPCRs-Targeted Drug Discovery Summit
Presenter: Dr. Gary S. Jacob, CEO of OKYO Pharma
Presentation Title: Clinical Development of Urcosimod, Targeting CMKLR1 (ChemR23), to Treat Neuropathic Corneal Pain
Date: Thursday, May 22, 2025
Location: Revere Hotel Boston Common, Boston, MA
About Neuropathic Corneal Pain (NCP)
NCP
is a condition that causes severe pain and sensitivity of the eyes, face, or head. The exact cause of NCP is unknown but is thought to result from nerve damage to the
cornea
combined with
inflammation
. NCP, which can exhibit as a severe, chronic, debilitating condition in patients suffering from a host of ophthalmic conditions, is presently treated, with limited success, by various topical and systemic treatments in an off-label fashion.
About Urcosimod (formerly called OK-101)
Urcosimod is a lipid conjugated chemerin peptide agonist of the ChemR23 G-protein coupled receptor which is typically found on immune cells of the eye responsible for the inflammatory response, as well as on neurons and glial cells in the dorsal root ganglion. Urcosimod was developed using a membrane-anchored-peptide technology to produce a novel long-acting drug candidate for treating dry eye disease. Urcosimod has been shown to produce anti-inflammatory and pain-reducing activities in mouse models of dry eye disease and corneal neuropathic pain, respectively, and is designed to combat washout through the inclusion of the lipid anchor built into the drug molecule to potentially enhance the residence time of urcosimod within the ocular environment. Urcosimod showed clear statistical significance in multiple endpoints in a 240-patient Phase 2, multi-center, double-masked, placebo-controlled trial to treat dry eye disease, and is presently being evaluated in a just-completed randomized, placebo-controlled, double-masked Phase 2 trial involving 17 neuropathic corneal pain patients.
About OKYO
OKYO Pharma Limited (NASDAQ: OKYO) is a clinical stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic corneal pain and dry eye disease, with ordinary shares listed for trading on the NASDAQ Capital Market. OKYO is focused on the discovery and development of novel molecules to treat neuropathic corneal pain and ocular diseases. In addition to the completed Phase 2 trial of urcosimod to treat dry eye disease patients, OKYO is also currently evaluating urcosimod to treat neuropathic corneal pain patients in a Phase 2 trial.
For further information, please visit www.okyopharma.com .
Enquiries:
| OKYO Pharma Limited | Gary S. Jacob, Chief Executive Officer | 917-497-7560 |
| Business Development & Investor Relations | Paul Spencer |
+44 (0)20 7495 2379
|
